Kyn Therapeutics Banks $49M to Advance Cancer Immunometabolism Therapies Post author:Sam Post published:December 13, 2017 Post category:BioPharma Investors were Atlas Venture and OrbiMed. Source: BioSpace You Might Also Like Tandem Diabetes Care Reports Second Quarter 2017 Financial Results July 27, 2017 Argenx To Host Conference Call & Webcast To Report Second Quarter Business Update And Half Year 2017 Financial Results On August 24, 2017 August 16, 2017 The Alliance for Regenerative Medicine (ARM) Releases Q2 2017 Data Report, Highlighting Sector Trends And Metrics August 17, 2017
Argenx To Host Conference Call & Webcast To Report Second Quarter Business Update And Half Year 2017 Financial Results On August 24, 2017 August 16, 2017
The Alliance for Regenerative Medicine (ARM) Releases Q2 2017 Data Report, Highlighting Sector Trends And Metrics August 17, 2017
